Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Suzhou Basecare Medical Corp. Ltd. Class H ( (HK:2170) ) has provided an update.
Suzhou Basecare Medical Corporation Limited reported 2025 revenue of RMB233.3 million, down from RMB299.1 million in 2024, while narrowing its operating loss and improving gross margins through cost controls and a refined product and regional mix. Net assets fell to RMB934.7 million from RMB1.14 billion as the company prioritized profitability, cash flow and business structure optimization over pure top-line growth.
Management described 2025 as a pivotal transition year, shifting the business from an R&D and registration-led model to commercialization and operational optimization, focusing resources on high-return products and key markets with long-term platform value. The group achieved major milestones in China, including registration of its Geri Time-Lapse Incubator, breakthroughs for the Gems embryo culture media series, approval of a sperm testing device, and ongoing expansion of its genetic testing closed-loop around PGT solutions, strengthening its domestic substitution prospects and regulatory moat.
The most recent analyst rating on (HK:2170) stock is a Sell with a HK$2.00 price target. To see the full list of analyst forecasts on Suzhou Basecare Medical Corp. Ltd. Class H stock, see the HK:2170 Stock Forecast page.
More about Suzhou Basecare Medical Corp. Ltd. Class H
Suzhou Basecare Medical Corporation Limited operates in the assisted reproduction sector, supplying reproductive centers and related medical institutions with automated, standardized and intelligent medical devices, reagents, consumables and integrated lab solutions. Its portfolio spans genetic testing, embryo culture, cryopreservation, andrology testing and laboratory information management, and it is evolving from a single genetic testing focus into a full-scenario supplier for assisted reproductive laboratories worldwide.
Average Trading Volume: 154,449
Technical Sentiment Signal: Sell
Current Market Cap: HK$547.1M
See more data about 2170 stock on TipRanks’ Stock Analysis page.